Please login to the form below

Not currently logged in
Email:
Password:

Lilly Neuroscience

This page shows the latest Lilly Neuroscience news and features for those working in and with pharma, biotech and healthcare.

Lilly posts higher-than-expected profit as new drugs lift outlook

Lilly posts higher-than-expected profit as new drugs lift outlook

diabetes, oncology, immunology and neuroscience,” said David Ricks, Lilly's chairman and CEO. ... Looking forward to 2020, Lilly now expects sales of at least $23.7bn, an increase on previous guidance of $23.6bn.

Latest news

  • Eli Lilly shutters UK neuroscience unit, with 80 job losses expected Eli Lilly shutters UK neuroscience unit, with 80 job losses expected

    Company says decision is not related to Brexit. Eli Lilly has said it plans to shut down its Windlesham research centre in Surrey, UK, which focused on neuroscience R&D, but ... It also said shifting the neuroscience projects to the US will make it

  • Lilly planning 20 new launches by 2023 Lilly planning 20 new launches by 2023

    Lilly's neuroscience R&D portfolio is headed by its Alzheimer's disease (AD) programmes, which include seven candidates headed by AstraZeneca-partnered BACE inhibitor AZD3293, and has recently started phase ... as an attractive partner for external

  • AZ and Lilly start BACE inhibitor trial in Alzheimer's AZ and Lilly start BACE inhibitor trial in Alzheimer's

    AZ and Lilly formed an alliance to develop AZD3293 (also known as LY3314814) back in September, with AZ drawing on Lilly's earlier experience with the emerging drug class. ... Together with Lilly, we have unique expertise that will allow us to evaluate

  • Lilly exploring diabetes portfolio for Alzheimer's potential Lilly exploring diabetes portfolio for Alzheimer's potential

    We're certainly doing some preclinical investigation of the potential of that kind of approach,” Lilly's chief scientific officer for neuroscience Dr Mike Hutton told PMLiVE. ... Read the full interview with Lilly's Dr Mike Hutton in the November issue

  • Lilly launches innovation platform

    Eli Lilly &Company has launched a drug discovery platform focusing on developing treatments in areas of unmet medical need. ... Data reports are then provided for them. In the case of cancer, endocrine, cardiovascular and neuroscience screenings, Lilly

More from news
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Interview: Mike Hutton, Lilly Interview: Mike Hutton, Lilly

    Nevertheless, unlike some of its peers Lilly has been clear and unwavering in its long-term commitment to neuroscience research. . ... It's at this leafy, Surrey site that I met Lilly's chief scientific officer for neurodegenerative diseases Dr Mike

  • Interview: Jan Lundberg, Eli Lilly Interview: Jan Lundberg, Eli Lilly

    We talk to Jan Lundberg, executive VP, science and technology, and president, Lilly Research Laboratories. ... These priorities could be seen in Lilly's own development plans, Lundberg continued, stating that the company had three products each in

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...